Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen

Core Insights - Eli Lilly has launched a new multi-dose injection pen for its obesity drug Zepbound, named KwikPen, which offers a month's worth of doses in a single device [1][3] - The price for the KwikPen starts at $299 per month for the lowest dose level, available through Lilly's direct-to-consumer platform, LillyDirect [1][3] - The introduction of the KwikPen aims to enhance patient convenience by reducing the number of devices needed for treatment, as it allows patients to take four weekly doses with one pen [2][3] Market Performance - Zepbound has seen significant demand since its market entry in late 2023, contributing to Eli Lilly's majority share in the weight-loss drug market, overtaking rival Novo Nordisk [3][4] - In the fourth quarter, Zepbound generated $4.2 billion in U.S. revenue, marking a 122% increase compared to the previous year [4] - The FDA has approved a label expansion for Zepbound to include the new multi-dose device, indicating regulatory support for the product's growth [4] Strategic Commitment - Eli Lilly emphasizes its commitment to supporting individuals with obesity through innovative treatment options like the Zepbound KwikPen, which is already trusted for other Lilly medications [5]